Compare BridgeBio Pharma Inc (BBIO) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wix.Com Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Wix.Com Ltd trades at $66.58 (market cap $2.61B). The key difference: BridgeBio Pharma Inc is far larger — about 6.4× Wix.Com Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | WIX | |
|---|---|---|
Market Cap | $16.61B | $2.61B |
Sector | Health | Technology |
52-Week High | $90.17 | $184.24 |
52-Week Low | $47.29 | $40.43 |
Enterprise Value | $18.16B | $3.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Wix trades at $60.20, down 1.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75 suggesting significant upside. Revenue grew to $1.99 billion in 2025, though net income margin remains negative at -8.19%. Recent earnings show three beats and one miss in the last four quarters, with a notable 27% price drop following the Q1 2026 miss.
The outlook is mixed: strong revenue growth and analyst optimism contrast with profitability challenges and a securities class action lawsuit alleging misleading statements. The stock offers potential for appreciation if execution improves, but faces near-term legal and operational risks that could pressure the share price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
